FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896449097> ?p ?o ?g. }

• W2896449097 endingPage "6945" @default.
• W2896449097 startingPage "6937" @default.
• W2896449097 abstract "Data of standard tyrosine kinase inhibitor (TKI) treatment outcome in next-generation sequencing (NGS)-identified ROS1-rearranged non-small-cell lung cancer (NSCLC) were rare. Thus, it is practical and necessary to evaluate the efficacy and influential factors of crizotinib in real-world practice.A total of 1,466 NSCLC patients with positive targeted NGS test results from September 2015 to January 2018 were enrolled in this real-world retrospective study. Twenty-two patients had ROS1 rearrangement detected by NGS. The efficacy and safety of crizotinib were evaluated. Subgroups of concomitant mutations, brain metastasis, and fusion variants were also analyzed.Among all the patients, the occurrence rate of ROS1 rearrangement was 1.5% (22 of 1,466). Ten ROS1 fusion partners were detected, and the most common variant was CD74, which accounted for 50% (11 of 22). Five patients were found to carry dual ROS1 fusion partners, and 23% (5 of 22) of patients were detected with concomitant mutations, including TP53&PIK3CA&mTOR mutation, TP53&CDKN2A mutation, TP53&BRCA2 mutation, ALK missense mutation (p.R311H), and MET amplification. Among 22 patients with ROS1-rearranged NSCLC, 20 patients were diagnosed at stage IV, and 19 patients received crizotinib treatment. The average follow-up period was 16 months. The overall response rate (ORR) of crizotinib in unselected crizotinib-treated patients was 89%, and the median progression-free survival time (mPFS) was 13.6 months. It was shown that NSCLC patients with exclusive ROS1 rearrangement had a longer PFS than those carrying concomitant mutations (15.5 vs 8.5 months, P=0.0213). There were no newly occurring intolerant adverse events in this study.Crizotinib is highly effective in NGS-identified ROS1-rearranged advanced NSCLC in real-word clinical practice, and the data are consistent with previous clinical trials applying fluorescence in situ hybridization/real-time PCR for ROS1 companion diagnosis. Concomitant mutations may not be rare and may deteriorate the PFS of crizotinib in patients with ROS1-rearranged NSCLC." @default.
• W2896449097 created "2018-10-26" @default.
• W2896449097 creator A5006478561 @default.
• W2896449097 creator A5012598663 @default.
• W2896449097 creator A5023694591 @default.
• W2896449097 creator A5024343477 @default.
• W2896449097 creator A5057960953 @default.
• W2896449097 creator A5062852782 @default.
• W2896449097 creator A5063481044 @default.
• W2896449097 creator A5069432515 @default.
• W2896449097 creator A5076756498 @default.
• W2896449097 creator A5082825584 @default.
• W2896449097 date "2018-10-01" @default.
• W2896449097 modified "2023-10-16" @default.
• W2896449097 title "Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer" @default.
• W2896449097 cites W1228651778 @default.
• W2896449097 cites W1666785645 @default.
• W2896449097 cites W1970822548 @default.
• W2896449097 cites W1990626198 @default.
• W2896449097 cites W2003876192 @default.
• W2896449097 cites W2039651814 @default.
• W2896449097 cites W2094973730 @default.
• W2896449097 cites W2100393058 @default.
• W2896449097 cites W2101441514 @default.
• W2896449097 cites W2126927831 @default.
• W2896449097 cites W2130488043 @default.
• W2896449097 cites W2137460778 @default.
• W2896449097 cites W2143367532 @default.
• W2896449097 cites W2148332636 @default.
• W2896449097 cites W2168691181 @default.
• W2896449097 cites W2168704289 @default.
• W2896449097 cites W2168933068 @default.
• W2896449097 cites W2168977308 @default.
• W2896449097 cites W2183178428 @default.
• W2896449097 cites W2228467092 @default.
• W2896449097 cites W2278778992 @default.
• W2896449097 cites W2313906428 @default.
• W2896449097 cites W2412900786 @default.
• W2896449097 cites W2509633441 @default.
• W2896449097 cites W2517708875 @default.
• W2896449097 cites W2605081625 @default.
• W2896449097 cites W2767917908 @default.
• W2896449097 cites W2768783909 @default.
• W2896449097 cites W2773047593 @default.
• W2896449097 cites W2794491531 @default.
• W2896449097 cites W2794757329 @default.
• W2896449097 cites W2794883050 @default.
• W2896449097 cites W2799433694 @default.
• W2896449097 cites W2800286167 @default.
• W2896449097 doi "https://doi.org/10.2147/ott.s176273" @default.
• W2896449097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6199224" @default.
• W2896449097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410351" @default.
• W2896449097 hasPublicationYear "2018" @default.
• W2896449097 type Work @default.
• W2896449097 sameAs 2896449097 @default.
• W2896449097 citedByCount "14" @default.
• W2896449097 countsByYear W28964490972019 @default.
• W2896449097 countsByYear W28964490972020 @default.
• W2896449097 countsByYear W28964490972021 @default.
• W2896449097 countsByYear W28964490972022 @default.
• W2896449097 countsByYear W28964490972023 @default.
• W2896449097 crossrefType "journal-article" @default.
• W2896449097 hasAuthorship W2896449097A5006478561 @default.
• W2896449097 hasAuthorship W2896449097A5012598663 @default.
• W2896449097 hasAuthorship W2896449097A5023694591 @default.
• W2896449097 hasAuthorship W2896449097A5024343477 @default.
• W2896449097 hasAuthorship W2896449097A5057960953 @default.
• W2896449097 hasAuthorship W2896449097A5062852782 @default.
• W2896449097 hasAuthorship W2896449097A5063481044 @default.
• W2896449097 hasAuthorship W2896449097A5069432515 @default.
• W2896449097 hasAuthorship W2896449097A5076756498 @default.
• W2896449097 hasAuthorship W2896449097A5082825584 @default.
• W2896449097 hasBestOaLocation W28964490971 @default.
• W2896449097 hasConcept C117643217 @default.
• W2896449097 hasConcept C121608353 @default.
• W2896449097 hasConcept C126322002 @default.
• W2896449097 hasConcept C143998085 @default.
• W2896449097 hasConcept C2775999482 @default.
• W2896449097 hasConcept C2776232967 @default.
• W2896449097 hasConcept C2776256026 @default.
• W2896449097 hasConcept C2778164965 @default.
• W2896449097 hasConcept C2779013556 @default.
• W2896449097 hasConcept C2779384505 @default.
• W2896449097 hasConcept C2779422266 @default.
• W2896449097 hasConcept C2780265364 @default.
• W2896449097 hasConcept C2781182431 @default.
• W2896449097 hasConcept C502942594 @default.
• W2896449097 hasConcept C71924100 @default.
• W2896449097 hasConceptScore W2896449097C117643217 @default.
• W2896449097 hasConceptScore W2896449097C121608353 @default.
• W2896449097 hasConceptScore W2896449097C126322002 @default.
• W2896449097 hasConceptScore W2896449097C143998085 @default.
• W2896449097 hasConceptScore W2896449097C2775999482 @default.
• W2896449097 hasConceptScore W2896449097C2776232967 @default.
• W2896449097 hasConceptScore W2896449097C2776256026 @default.
• W2896449097 hasConceptScore W2896449097C2778164965 @default.
• W2896449097 hasConceptScore W2896449097C2779013556 @default.
• W2896449097 hasConceptScore W2896449097C2779384505 @default.

• next